Nicorandil Tablets 10mg مالطا - الإنجليزية - Medicines Authority

nicorandil tablets 10mg

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - nicorandil - tablet - nicorandil 10 mg - cardiac therapy

CLOSANTEL SODIUM أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

closantel sodium

boehringer ingelheim animal health australia pty. ltd. - closantel - unknown - closantel anthelmintic active 0.0 - active constituent

Closantel Sodium أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

closantel sodium

virbac (australia) pty ltd - closantel sodium - unknown - closantel sodium ungrouped active 0.0 - active constituent

CLOSANTEL BASE أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

closantel base

jurox pty limited - closantel - unknown - closantel anthelmintic active 0.0 - active constituent

Closantel Plus نيوزيلاندا - الإنجليزية - Ministry for Primary Industries

closantel plus

nexan corporation limited - closantel sodium; abamectin - closantel sodium 51.66 g/litre; abamectin 1 g/litre

Nicorandil (Max Health) نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

nicorandil (max health)

max health limited - nicorandil 10mg - tablet - 10 mg - active: nicorandil 10mg excipient: croscarmellose sodium mannitol pregelatinised maize starch stearic acid - nicorandil is indicated for the symptomatic treatment of patients with stable angina pectoris that is inadequately controlled or have a contraindication or intolerance to first-line anti-anginal therapies.

Nicorandil (Max Health) نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

nicorandil (max health)

max health limited - nicorandil 20mg - tablet - 20 mg - active: nicorandil 20mg excipient: croscarmellose sodium mannitol pregelatinised maize starch stearic acid - nicorandil is indicated for the symptomatic treatment of patients with stable angina pectoris that is inadequately controlled or have a contraindication or intolerance to first-line anti-anginal therapies.